Abstracts Archive - Page 469 of 2605 - ACR Meeting Abstracts

Abstract Number: 2510 • ACR Convergence 2023
Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1
Tineke van Wesemael¹, Jessica Borgers², Kyra Gelderman³, Els Verdegaal⁴, C.M. Korse⁵, M.J.P. Welters⁶, Ellen Kapiteijn⁷, W.J. van Houdt², Sjoerd van der Burg⁶, René Toes¹, J.V. Thienen², John Haanen² and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, ³Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Amsterdam, Netherlands, ⁵Department of Laboratory Medicine, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, Netherlands, ⁶Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands, ⁷Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: PD-1 immune checkpoint inhibitors are able to re-activate restrained anti-tumor T-cell responses in melanoma patients. However, PD-1 inhibition may also activate auto-reactive T-cells leading…
Abstract Number: 2557 • ACR Convergence 2023
Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Nicholas Boire¹, Melanie Bois¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Matthew Koster¹, Cornelia M. Weyand³ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…
Abstract Number: 2594 • ACR Convergence 2023
Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Oliver Distler¹, Madelon Vonk², Arata Azuma³, Maureen Mayes⁴, Dinesh Khanna⁵, Kristin B Highland⁶, Gerrit Toenges⁷, Margarida Alves⁸ and Yannick Allanore⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan, and Meisei Hospital, Saitama, Japan, ⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Cleveland Clinic, Cleveland, OH, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…
Abstract Number: 2573 • ACR Convergence 2023
Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality
Michelle Ghebranious, Elena Joerns, Traci Adams and Trushil Shah, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) that manifests with interstitial pneumonia and features of autoimmunity while…
Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Christoph Berger², Christos Polysopoulos¹, Adrian Ciurea³, Diego Andrey⁴, Tanja Maletic¹, Myriam Riek¹, Almut Scherer¹, Isabell von Loga¹, Judith Safford¹, Kim Lauper⁵, Burkhard Moeller⁶, Nicolas Vuilleumier⁴, Axel Finckh⁷ and Andrea Rubbert-Roth⁸, ¹SCQM Foundation, Zurich, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Zurich, Zürich, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Geneva University Hospitals, Genève, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷HUG, Geneva, Switzerland, ⁸Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…
Abstract Number: 2561 • ACR Convergence 2023
The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group
Alessandro Tomelleri¹, Corrado Campochiaro², Francesco Muratore³, Sara Monti⁴, Nicola Farina⁵, Chiara Marvisi⁶, Elena Galli⁷, Alessandra Milanesi⁸, Naomi Viapiana⁵, Alvise Berti⁹, Roberto Bortolotti⁹, Milena Bond¹⁰, Roberto Padoan¹¹, Mara Felicetti⁹, Franco Schiavon¹², Carlotta Nannini¹³, Fabrizio Cantini¹³, Alessandro Giollo¹⁴, Maurizio Rossini¹⁵, Edoardo Conticini¹⁶, Bruno Frediani¹⁷, Fabrizio Conti¹⁸, Roberta Priori¹⁸, Marco Sebastiani¹⁹, Giulia Cassone²⁰, Luca Quartuccio Quartuccio²¹, Elena Treppo²², Silvano Bettio²³, Ariela Hoxha²⁴, Marco Lovisotto²⁴, Giacomo Emmi²⁵, irene mattioli²⁶, Pietro Leccese²⁷, Roberto F. Caporali²⁸, Lorenza Maria Argolini²⁹, Rosario Foti³⁰, Elisa Visalli³⁰, Michele Colaci³¹, Carlomaurizio Montecucco³², Lorenzo Dagna³³ and Carlo Salvarani³⁴, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁵IRCCS San Raffaele Hospital, Milan, Italy, ⁶IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁷Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁸Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁹Santa Chiara Hospital of Trento, Trento, Italy, ¹⁰Azienda sanitaria dell'Alto Adige, Merano, Italy, ¹¹Department of Medicine DIMED, University of Padova, Padova, Italy, ¹²University of Padova, Padova, Italy, ¹³Santo Stefano Hospital Prato, Prato, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁵Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ¹⁶Tallaght University Hospital, Dublin, Ireland, ¹⁷University of Siena, Siena, Italy, ¹⁸University of Rome La Sapienza, Rome, Italy, ¹⁹Azienda Policlinico di Modena, Modena, Italy, ²⁰University of Modena and Reggio Emilia, Modena, Italy, ²¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²²Physician, Moimacco, Italy, ²³University of Padua, Treviso, Italy, ²⁴San Bortolo Hospital of Vicenza, Vicenza, Italy, ²⁵University of Florence, Florence, Italy, ²⁶University of Florence, Firenze, Italy, ²⁷Regional Hospital San Carlo, Potenza, Italy, ²⁸Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ²⁹ASST Gaetano Pini, Milano, Italy, ³⁰AOU San Marco, Catania, Catania, Italy, Catania, Italy, ³¹University of Catania, Catania, Italy, ³²Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy, ³³Ospedale San Raffaele, Milano, Italy, ³⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The 2022 classification criteria for giant cell arteritis (GCA) have been recently published. The aim of this study is to investigate whether the score…
Abstract Number: 2570 • ACR Convergence 2023
Thrombosis in Patients with VEXAS Syndrome: A Retrospective Cohort Study
Atefeh Ghorbanzadeh¹, Yael Kusne², Alina Dulau-Florea³, Ruba Shalhoub³, Pedro Alcedo³, Khanh Nghiem³, Marcela Ferrada⁴, alexander hines¹, Sumith Panicker³, amanda ombrello⁵, Kaaren K. Reichard¹, Ivana Darden³, Wendy Goodspeed³, Lorena wilson³, Horatiu Olteanu¹, Terra L. Lasho¹, Daniel Kastner⁶, Kenneth Warrington¹, Abhishek A. Mangaonkar¹, Ronald Go¹, David Beck⁷, Mrinal S. Patnaik¹, Neal S. Young⁸, Katherine R. Calvo³, Ana Casanegra⁹, Peter Grayson¹⁰, Matthew Koster¹, Colin O Wu³, Damon E. Houghton⁹, Bhavisha Patel¹¹, Yogen Kanthi¹² and Emma M. Groarke¹³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Phoenix, AZ, ³National Institutes of Health (NIH), Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵National Institutes of Health, Rockville, MD, ⁶National Human Genome Research Institute, Bethesda, MD, ⁷New York University, New York, NY, ⁸National Institutes of Health (NIH), Rochester, MD, ⁹Mayo Clinic, Rochester, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹¹National Institutes of Health, Beltsville, MD, ¹²National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, ¹³Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, due to somatic mutations in the UBA1 gene, is an autoinflammatory disorder associated with an increased…
Abstract Number: 2555 • ACR Convergence 2023
Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction
YuFang Ding¹, Qian Wang¹, Xinping Tian², Mengtao Li², xiaofeng Zeng¹ and Jiuliang zhao², ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Serologically active clinically quiescent (SACQ) is a clinical state of systemic lupus erythematosus (SLE) characterized by high levels of serologic markers without clinical activity.…
Abstract Number: 2591 • ACR Convergence 2023
Under Assault: Ongoing Brain Dysfunction Identified on Resting State-functional MRI (rs-fMRI) in SLE Patients in Clinical Remission
Meggan MacKay, an vo, Erik Anderson, Cynthia Aranow, Betty Diamond and David Eidelberg, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: There is substantial evidence that the brain is targeted early in SLE, likely from disease inception. Data from mouse models and human studies suggest…
Abstract Number: 2572 • ACR Convergence 2023
Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival
Elena Joerns¹, Chad Newton², Stanislav Kolenikov³, Jeffrey Sparks⁴ and David Karp⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³NORC at the University of Chicago, Columbia, MO, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The term interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and features of autoimmunity, that do not fulfill classification…
Abstract Number: 2523 • ACR Convergence 2023
Region, Race, and Hospital Factors Impact Length of Stay and Hospital Charges Post-primary Total Knee Arthroplasty
Kranti Rumalla¹, Sumanth Chandrupatla² and Jasvinder Singh², ¹Northwestern School of Medicine, Chicago, IL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteoarthritis (OA) affects nearly 33 million adults in the US and total knee arthroplasty (TKA) is an effective treatment. Outcomes can vary by regional…
Abstract Number: 2428 • ACR Convergence 2023
Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Natalie McCormick¹, Kehuan Lin², Chio Yokose³, Na Lu⁴, Yuqing Zhang¹ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…
Abstract Number: 2435 • ACR Convergence 2023
Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics
Marie Binvignat¹, Brenda Miao², Camilla Wibrand³, Monica Yang⁴, Dmitry Rychkov⁵, Emily Flynn⁴, Umair Khan⁴, Joanne Nititham⁶, Alex Carvidi⁴, Melissa Krueger⁴, Erene Niemi⁴, Yang Sun⁴, Gabriella Fragiadakis⁴, David Klatzmann¹, Jeremie SELLAM⁷, Encarnita Mariotti-Ferrandiz¹, Andrew Gross⁴, Chun Jimmie Ye⁴, Atul Butte⁴, Lindsey Criswell⁶, Mary Nakamura⁸ and Marina Sirota⁵, ¹Sorbonne Université, Paris, France, ²University of California San Francisco, Fremont, CA, ³Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA, ⁶NIH/NHGRI, Bethesda, MD, ⁷Sorbonne Université APHP, Paris, France, ⁸UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Single cell transcriptional profiling (scRNA-Seq) is valuable in identifying gene signatures and cell subpopulations associated with rheumatoid arthritis (RA). However prior studies have often…
Abstract Number: 2067 • ACR Convergence 2023
A New Tool Assessing Trainees’ Interventional Musculoskeletal Ultrasound Skills
Stine Maya Dreier Carstensen¹, Lene Terslev², Søren Just³, Mikkel Østergaard⁴, Mogens Pfeiffer-Jensen¹ and Lars Konge⁵, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital – Rigshospitalet Glostrup, Copenhagen, Denmark, ²Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ³Section of Rheumatology, Department of Medicine, Odense University Hospital – Svendborg Hospital, Odense, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁵Copenhagen Academy for Medical Education and Simulation The Capital Region of Denmark, Copenhagen, Denmark
Background/Purpose: Interventional musculoskeletal ultrasound (MSUS) procedures, such as ultrasound-guided arthrocentesis and joint injections, are routinely used in rheumatology practice. However, the efficacy and safety of…
Abstract Number: 0357 • ACR Convergence 2023
Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting
Pamela F. Weiss¹, Nicolino Ruperto², Erhard Quebe-Fehling³, Alexis Shew⁴, Luminita Pricop⁵, Christelle Pieterse³ and Hermine Brunner⁶, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, St. Louis, MO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The juvenile spondyloarthritis disease activity index (JSpADA) is a disease activity assessment tool developed for children with juvenile psoriatic arthritis (JPsA) and enthesitis related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].